好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Indentifying the Correlates of Pseudobulbar Affect in Patients with Parkinsonsonian Disorders and ALS
Behavioral Neurology
P05 - (-)
125
BACKGROUND: PBA is a frontal disinhibition syndrome associated with inappropriate laughter and crying to a minor stimulus, independent of affective disturbance. PBA is common in ALS and recognised in PD and aP. Determinants of PBA have not been systematically studied.
DESIGN/METHODS: Patients recruited from a movement disorders or ALS clinic completed a Montreal Cognitive Assesement (MoCA) and self-report questionnaires [Center for Neurological Study- Lability Scale for PBA (CNS-LS), Beck Depression Inventory-II (BDI), State-Trait Anxiety Inventory (STAI), Self and Other Apathy Evaluation Scale (AES), and the Short form-36 (SF-36) quality of life (QOL) measure]. Statistical analyses included ANOVAs for group differences, Pearson correlations for relationships between PBA and co-morbidities, and Chi-square/t-tests for demographic variables.
RESULTS: 53 PD, 20 aP and 21 ALS patients participated. There were no differences between groups in age, gender, education, race or age of disease onset. There were no statistically significant differences in CNS-LS scores between groups (PD: 10.11 卤3.83; aP: 12.15 卤 5.04; ALS: 12.25 卤 7.5; F=1.93 p=0.15). In the PD and aP groups, anxiety scores positively correlated with PBA, while this association was not found for the ALS group. Depression and Mental Health QOL impairments also positively correlated with PBA scores for only the PD group. MoCA scores were not correlated with PBA for any of the groups.
CONCLUSIONS: Despite its definition, PBA correlates with affective disturbance in PD and aP patients but not ALS, suggesting that individuals with Parkinsonian disorders and PBA symptoms should be evaluated and/or treated for co-morbid mood problems. Furthermore, this preliminary study suggests alternate pathophysiologic mechanisms for PBA in ALS compared to PD and aP.
Authors/Disclosures
Neepa J. Patel, MD, FAAN (Rush University Medical Center)
PRESENTER 		Dr. Patel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie Pharmaceuticals. Dr. Patel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amneal Pharmaceuticals. Dr. Patel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernius Pharmaceuticals. Dr. Patel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Boston Scientific.
Michele K. York, PhD, ABPP-CN (Baylor College of Medicine) Dr. York has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for RAD-PD. The institution of Dr. York has received research support from Michael J. Fox Foundation. The institution of Dr. York has received research support from NIH. The institution of Dr. York has received research support from Takeda.
Cecile L. Phan, MD (Baylor College of Medicine) Dr. Phan has nothing to disclose.
Joohi Jimenez Shahed, MD, FAAN (Icahn School of Medicine at Mount Sinai) Dr. Jimenez Shahed has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Dr. Jimenez Shahed has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Medtronic. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Jimenez Shahed has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for BlueRock. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Treefrog. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for RebrAIn. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BlueRock Therapeutics. Dr. Jimenez Shahed has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PhotoPharmics. Dr. Jimenez Shahed has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Emalex. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. The institution of Dr. Jimenez Shahed has received research support from Amneal. The institution of Dr. Jimenez Shahed has received research support from Annovis. The institution of Dr. Jimenez Shahed has received research support from SAGE. The institution of Dr. Jimenez Shahed has received research support from Ono Pharmaceuticals. The institution of Dr. Jimenez Shahed has received research support from BlueRock. The institution of Dr. Jimenez Shahed has received research support from Neuron23. Dr. Jimenez Shahed has received personal compensation in the range of $0-$499 for serving as a Faculty with Movement Disorders Society. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Faculty with 好色先生. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Grant Reviewer with Parkinson Foundation.
Timothy L. Vollmer, MD, FAAN The institution of Dr. Vollmer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen IDEC. The institution of Dr. Vollmer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech/Roche. The institution of Dr. Vollmer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Siranax. The institution of Dr. Vollmer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene. The institution of Dr. Vollmer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. The institution of Dr. Vollmer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Meyers Squib. The institution of Dr. Vollmer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Viela Bios. The institution of Dr. Vollmer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. The institution of Dr. Vollmer has received research support from Rocky Mountain MS Center. The institution of Dr. Vollmer has received research support from Biogen. The institution of Dr. Vollmer has received research support from Actelion. The institution of Dr. Vollmer has received research support from Genentech/Roche. The institution of Dr. Vollmer has received research support from Anokion. The institution of Dr. Vollmer has received research support from TG Therapeutics.